-
$1 Billion Deal For Moderna To Expand Product Pipeline In China
Friday, July 7, 2023 - 8:45am | 838Read More...The defensive stocks sector has been underperforming most - if not all - of the remaining cyclical sectors in the U.S. economy. These preferences come from underlying dynamics in the money markets and where investors think we are in the business cycle. These preferences can be visually spotted by...
-
Quarter Ends With Focus On Regeneron's Virus Cocktail, Disney Layoffs, Micron Results
Wednesday, September 30, 2020 - 10:51am | 2183Read More...Anyone hoping last night’s debate would calm the political waters arguably didn’t get their wish, and that could be one reason stock indices remain under pressure early Wednesday. As one person wrote on Twitter Inc (NYSE: TWTR), “The next debate is probably going...
-
3 Pharma Stocks That Are COVID-19 Resistant
Wednesday, September 2, 2020 - 11:30am | 1075Read More...The race for a novel coronavirus vaccine has lit a fuse under biotech and pharmaceutical companies. 2020 will surely be remembered as the year of COVID-19 and an unprecedented boom for these industries. During good times, pharma stocks are attractive because of their steady cash flow, high-profit...
-
Barron's Picks And Pans: Facebook, Nokia, Regeneron And More
Saturday, July 11, 2020 - 5:47pm | 687Read More...This weekend's Barron's cover story presents the results from the Barron's 2020 Midyear Roundtable. Other featured articles look how to manage risk in a time of market volatility and which companies the U.S. government is and is not bailing out. Also, the prospects for some retail...
-
Fintech Focus For July 3, 2020
Friday, July 3, 2020 - 9:26am | 1689Read More...Daily Perspective: Life is what happens when you're busy making other plans. - John Lennon Fintech Movers: An International Monetary Fund (IMF) official recently noted that China’s Fintech sector could be “instrumental” in assisting SMEs with acquiring reliable credit. The...
-
Regeneron Pharmaceuticals Gains A Bull Ahead Of Earnings
Friday, November 3, 2017 - 1:52pm | 507Read More...Ahead of Regeneron Pharmaceuticals Inc (NASDAQ: REGN)'s quarterly report, scheduled for Wednesday, Nov. 8, the company's shares won an upgrade. Regeneron shares fell beneath Baird's price target after an August downgrade, analyst Brian Skorney said in a Friday note. With better-than-...
-
Here's Why Ophthotech Is Trading Down On Regeneron's News
Friday, September 30, 2016 - 11:45am | 474Read More...Ophthotech Corp (NASDAQ: OPHT), a biopharmaceutical company that develops therapeutics for the treatment of eye diseases, saw its shares fall more than 13 percent Friday. The decline is attributed to an announcement by Regeneron Pharmaceuticals Inc (NASDAQ: REGN), a larger biopharmaceutical...
-
Regeneron Pharmaceuticals Loses 7% Following Q4 Miss
Tuesday, February 9, 2016 - 9:18am | 312Read More...Shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) were trading lower by around 7 percent early Tuesday morning after the company reported its fourth quarter results. Regeneron Pharmaceuticals said that it earned $2.83 per share in the fourth quarter on revenue of $1.16 billion. Wall Street...
-
Regeneron, Sanofi Announce FDA Has Accepted For Review BLA For Sarilumab
Friday, January 8, 2016 - 11:36am | 180Read More...Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (ADR) (NYSE: SNY) jointly announced Friday morning that the U.S. Food and Drug Administration has accepted for review the Biologics License Application (BLA) for sarilumab. Regeneron noted that the BLA for sarilumab contains data from...
-
Regeneron Shares Rising After Sanofi Collaboration Revealed: Good News For Shareholders?
Tuesday, July 28, 2015 - 1:57pm | 429Read More...Shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) were trading higher by more than 3 percent Tuesday after the company announced a new global collaboration with Sanofi (NYSE: SNY) to "discover, develop and commercialize new antibody cancer treatments in the emerging field of immune-...
-
UPDATE: Barclays Initiates Coverage On Regeneron
Tuesday, January 6, 2015 - 12:28pm | 200Read More...Geoffrey Meacham of Barclays initiated coverage of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) on Tuesday with an Equal-Weight rating and $450 price target as approval and modest growth profile of key drugs are already expected by investors. Based on Meacham's survey of 50 U.S....
-
TGIF As Markets Rally; S&P 500 Posts Longest Weekly Loss Streak Since 2011
Friday, October 17, 2014 - 4:43pm | 2830Read More...U.S. stocks rallied on Friday following positive earnings reports from several large-cap multinationals this morning on a relatively light day of market moving news. The Dow traded higher by more than 300 points before giving back some of the gains. The S&P 500 rallied but still posted its...
-
The 20 Stocks with the Highest Share Price
Wednesday, May 15, 2013 - 12:48pm | 142Read More...It's official. With its shares eclipsing the $900 mark, Google (NASDAQ: GOOG) is trading in the nosebleeds. Out of curiosity, Benzinga decided to look where other publicly traded companies in the S&P 500 (NYSE: SPY) were trading at. This only includes the S&P 500 -- otherwise companies...
-
Short Sellers Shy Away from Biotech Firms
Monday, August 13, 2012 - 6:18am | 547Read More...The short interest data is out from the July 31 settlement date. By and large short sellers have retreated from gambles on biotech firms compared to the July 13 settlement date. A couple of notable exceptions were Dendreon (NASDAQ: DNDN), for which short interest was higher by 7 percent to 40.8...
-
Regeneron Increases Size of Public Offering of Common Stock
Friday, October 8, 2010 - 8:29am | 218Read More...Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has increased the size of its previously announced underwritten public offering of Common Stock from 4,500,000 shares to 5,500,000 shares and agreed to an indicative price of $28.00 per share for the offering. Citi is serving as...
